Evidence map›Paper›PMID 39827117›Full record

ArticleJournal of neurodevelopmental disorders2025

Resting state EEG in young children with Tuberous Sclerosis Complex: associations with medications and seizures.

Caitlin C Clements, Anne-Michelle Engelstad, Carol L Wilkinson, Carly Hyde, Megan Hartney, Alexandra Simmons, Helen Tager-Flusberg, Shafali Jeste, Charles A Nelson

Abstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Caitlin C Clements *Department of Psychology, University of Notre Dame, 340 Corbett Family Hall Notre Dame, South Bend, IN, 46556, USA. cclemen2@nd.edu.
Anne-Michelle Engelstad *Laboratories of Cognitive Neuroscience, Division of Developmental Medicine, Boston Children's Hospital, Brookline, MA, USA.
Carol L Wilkinson *Laboratories of Cognitive Neuroscience, Division of Developmental Medicine, Boston Children's Hospital, Brookline, MA, USA.
Carly HydeSchool of Public Health, UCLA, Los Angeles, CA, USA.
Megan HartneyLaboratories of Cognitive Neuroscience, Division of Developmental Medicine, Boston Children's Hospital, Brookline, MA, USA.
Alexandra SimmonsLaboratories of Cognitive Neuroscience, Division of Developmental Medicine, Boston Children's Hospital, Brookline, MA, USA.
Helen Tager-FlusbergDepartment of Psychological & Brain Sciences, Boston University, Boston, MA, USA.
Shafali JesteDepartment of Neurology, Children's Hospital LA, Los Angeles, CA, USA.
Charles A NelsonLaboratories of Cognitive Neuroscience, Division of Developmental Medicine, Boston Children's Hospital, Brookline, MA, USA.

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
Neurobehavioral Research on Infants at Risk for SLI and AutismR01DC010290 · NIDCD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NELSON, CHARLES ALEXANDER, TAGER-FLUSBERG, HELEN · 2009 to 2020
$7.5M
Mechanisms of Change with Early Intervention in Tuberous Sclerosis ComplexR01HD090138 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESTE, SHAFALI SPURLING · 2017 to 2022
$3.1M
Translational Post-doctoral Training in NeurodevelopmentT32MH112510 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI DAVID C GLAHN, CHARLES Alexander NELSON · 2017 to 2026
$2.6M
Neural Markers of Language Development in Fragile X Syndrome and Autism Spectrum DisorderK23DC017983 · NIDCD · BOSTON CHILDREN'S HOSPITAL · PI WILKINSON, CAROL LEE · 2020 to 2024
$859k
Molecular mechanisms of aging in the intrinsic laryngeal musclesR03DC007983 · NIDCD · UNIVERSITY OF KENTUCKY · PI MCMULLEN, COLLEEN A · 2006 to 2009
$249k
National Institute of Child Health and Human Development R01HD090138NICHD NIH HHS P50 HD105351NICHD NIH HHS R01 HD090138NIDCD NIH HHS K23 DC017983NIDCD NIH HHS K23DC07983NIDCD NIH HHS R01 DC010290NIDCD NIH HHS R01DC010290NIDCD NIH HHS R03 DC007983NIMH NIH HHS T32 MH112510NIMH NIH HHS T32MH112510
6 · The paper itself

Abstract

backgroundTuberous Sclerosis Complex (TSC) is a rare genetic condition caused by mutation to TSC1 or TSC2 genes, with a population prevalence of 1/7000 births. TSC manifests behaviorally with features of autism, epilepsy, and intellectual disability. Resting state electroencephalography (EEG) offers a window into neural oscillatory activity and may serve as an intermediate biomarker between gene expression and behavioral manifestations. Such a biomarker could be useful in clinical trials as an endpoint or predictor of treatment response. However, seizures and antiepileptic medications also affect resting neural oscillatory activity and could undermine the utility of resting state EEG features as biomarkers in neurodevelopmental disorders such as TSC.

methodsThis paper compares resting state EEG features in a cross-sectional cohort of young children with TSC (n = 49, ages 12-37 months) to 49 age- and sex-matched typically developing controls. Within children with TSC, associations were examined between resting state EEG features, seizure severity composite score, and use of GABA agonists.

resultsCompared to matched typically developing children, children with TSC showed significantly greater beta power in permutation cluster analyses. Children with TSC also showed significantly greater aperiodic offset (reflecting nonoscillatory neuronal firing) after power spectra were parameterized using SpecParam into aperiodic and periodic components. Within children with TSC, both greater seizure severity and use of GABAergic antiepileptic medication were significantly and independently associated with increased periodic peak beta power.

conclusionsThe elevated peak beta power observed in children with TSC compared to matched typically developing controls may be driven by both seizures and GABA agonist use. It is recommended to collect seizure and medication data alongside EEG data for clinical trials. These results highlight the challenge of using resting state EEG features as biomarkers in trials with neurodevelopmental disabilities when epilepsy and anti-epileptic medication are common.

Indexed as

AnticonvulsantsElectroencephalographySeizuresTuberous SclerosisChild, PreschoolCross-Sectional StudiesFemaleHumansInfantMaleAnticonvulsantsBiomarkerEEGEpilepsyGABA agonistsSeizuresTuberous Sclerosis Complex

Identifiers

PMID39827117
PMCPMC11742757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.